First Time Loading...

Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 5.76 USD 2.31% Market Closed
Updated: Apr 29, 2024

Wall Street
Price Targets

CTKB Price Targets Summary
Cytek Biosciences Inc

Wall Street analysts forecast CTKB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTKB is 10.2 USD with a low forecast of 9.09 USD and a high forecast of 12.6 USD.

Lowest
Price Target
9.09 USD
58% Upside
Average
Price Target
10.2 USD
77% Upside
Highest
Price Target
12.6 USD
119% Upside
Cytek Biosciences Inc Competitors:
Price Targets
MXCT
MaxCyte Inc
160% Upside
PPGN
PolyPeptide Group AG
29% Downside
ERF
Eurofins Scientific SE
7% Upside
SYNGENE
Syngene International Ltd
9% Upside
688114
MGI Tech Co Ltd
88% Upside
WAT
Waters Corp
7% Upside
ABCL
Abcellera Biologics Inc
317% Upside
4YL
Nanoform Finland Oyj
77% Upside

Revenue
Forecast

Revenue Estimate
Cytek Biosciences Inc

For the last 3 years the compound annual growth rate for Cytek Biosciences Inc's revenue is 28%. The projected CAGR for the next 3 years is 14%.

28%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Cytek Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Cytek Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTKB's stock price target?
Price Target
10.2 USD

According to Wall Street analysts, the average 1-year price target for CTKB is 10.2 USD with a low forecast of 9.09 USD and a high forecast of 12.6 USD.

What is Cytek Biosciences Inc's Revenue forecast?
Projected CAGR
14%

For the last 3 years the compound annual growth rate for Cytek Biosciences Inc's revenue is 28%. The projected CAGR for the next 3 years is 14%.